Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  The Lancet

• Publication date

  1992-10-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0140-6736(92)92685-9PMID 1383656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neonatal screen for hereditary tyrosinaemia type I.

  1992cited by this paper
• Biphasic reduction and concanavalin A binding properties of serum alpha-fetoprotein in preterm and term infants.

  1991cited by this paper
• Neurologic crises in hereditary tyrosinemia.

  1990cited by this paper
• Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean.

  1990cited by this paper
• Liver cell dysplasia and early liver transplantation in hereditary tyrosinemia.

  1990cited by this paper
• Disorders of copper transport

  1989cited by this paper
• Urinary organic acids: isolation and quantification for routine metabolic screening.

  1987cited by this paper
• [19] 4-Hydroxyphenylpyruvate dioxygenase from human liver

  1987cited by this paper
• Hereditary tyrosinemia type I--an overview.

  1986cited by this paper
• Ionic calcium levels during pregnancy, at delivery and in the first hours of life.

  1986cited by this paper
• Hereditary tyrosinemia type I--an overview.

  1986cited by this paper
• Determination of urinary succinylacetone by capillary gas chromatography.

  1984cited by this paper
• Four-Hydroxyphenylpyruvic Acid Oxidase Deficiency with Normal Fumarylacetoacetase: a New Variant Form of Hereditary Hypertyrosinemia

  1983cited by this paper
• Chronic Tyrosinemia Associated with 4-Hydroxyphenylpyruvate Dioxygenase Deficiency with Acute Intermittent Ataxia and without Visceral and Bone Involvement

  1983cited by this paper
• Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.

  1982cited by this paper
• Inhibition of delta-aminolevulinic acid dehydrase by 4,6-dioxoheptanoic acid.

  1981cited by this paper
• On the enzymic defects in hereditary tyrosinemia.

  1977cited by this paper
• The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

  1976cited by this paper
• A study of the determination of 5-aminolevulinate hydro-lyase (delta-aminolevulinate dehydratase) activity in hemolysates of human erythrocytes.

  1971cited by this paper
• Exertion of delta-aminolevulinic acid in hereditary tyrosinemia.

  1969cited by this paper
• Excretion of δ-aminolevulinic acid in hereditary tyrosinemia

  1969cited by this paper
• TYROSINEMIA.

  1965cited by this paper

• Neurological crisis in tyrosinemia type 1: Essential roles of replacement therapy and nutrition in multidisciplinary management.

  2025cites this paper
• Harliku (nitisinone): first FDA-approved disease-modifying therapy for alkaptonuria

  2025cites this paper
• Nitisinone treatment protect hereditary tyrosinemia type I patients against inflammation, DNA and protein oxidative damage by decreasing succinylacetone levels

  2025cites this paper
• Anopheles mosquito survival and pharmacokinetic modeling show the mosquitocidal activity of nitisinone.

  2025cites this paper
• Deployment and transcriptional evaluation of nitisinone, an FDA-approved drug, to control bed bugs.

  2025cites this paper
• The β-triketone, nitisinone, kills insecticide-resistant mosquitoes through cuticular uptake

  2025cites this paper
• New treatment for pyridoxine-dependent epilepsy due to ALDH7A1 deficiency: first proof-of-principle of upstream enzyme inhibition in the mouse

  2025cites this paper
• Mode of toxicity of the β-triketone leptospermone to Aedes aegypti mosquitoes.

  2025cites this paper
• An Unusual Presentation of Tyrosinemia Type 1 in a Pediatric Patient: Case Report and Comprehensive Review

  2025cites this paper
• Overview of European Practices for Management of Tyrosinemia Type 1: Towards European Guidelines

  2025cites this paper
• NTBC dosing and outcomes in hereditary tyrosinemia type 1: insights from a representative human model and 99 patients

  2025cites this paper
• Metabolic rerouting of valine and isoleucine oxidation increases survival in zebrafish models of disorders of propionyl-CoA metabolism.

  2025cites this paper
• Killing of Anopheles stephensi mosquitoes by selective triketone 4-hydroxyphenylpyruvate dioxygenase inhibitors depends on a high protein meal.

  2025cites this paper
• In vivo expansion of gene-targeted hepatocytes through transient inhibition of an essential gene.

  2025cites this paper
• Integrating Machine Learning and Follow-Up Variables to Improve Early Detection of Hepatocellular Carcinoma in Tyrosinemia Type 1: A Multicenter Study

  2025cites this paper
• Dissecting the effect of mitochondrial BCAT inhibition in methylmalonic acidemia

  2025cites this paper
• Decoding hepatorenal tyrosinemia type 1: Unraveling the impact of early detection, NTBC, and the role of liver transplantation.

  2024cites this paper
• Liver fibrosis pathologies and potentials of RNA based therapeutics modalities

  2024cites this paper
• Diagnosis, treatment, management and monitoring of patients with tyrosinaemia type 1: Consensus group recommendations from the German‐speaking countries

  2024cites this paper
• Targeting AGAT gene expression – a drug screening approach for the treatment of GAMT deficiency

  2024cites this paper
• Oxidative Stress Associated With Increased Reactive Nitrogen Species Generation in the Liver and Kidney Caused by a Major Metabolite Accumulating in Tyrosinemia Type 1

  2024cites this paper
• A 12-month, longitudinal, intervention study examining a tablet protein substitute preparation in the management of tyrosinemia

  2024cites this paper
• A p21-ATD Mouse Model for Monitoring and Eliminating Senescent Cells and Its Application in Liver Regeneration post Injury.

  2024cites this paper
• Hereditary tyrosinaemia type 1 in the absence of succinylacetone: 4‐oxo 6‐hydroxyhepanoate (4OHHA), a putative diagnostic biomarker

  2024cites this paper
• CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells

  2024cites this paper
• UV-induced E/Z Isomerization of the Electron-Rich Pyrrole Ring Containing Diketoenols: Theoretical and Experimental Study

  2024cites this paper
• Self-delivering CRISPR RNAs for AAV Co-delivery and Genome Editing in vivo

  2023cites this paper
• The effects of phenylalanine and tyrosine levels on dopamine production in rat PC12 cells. Implications for treatment of phenylketonuria and tyrosinemia type 1

  2023cites this paper
• Liver disorders caused by inborn errors of metabolism.

  2023cites this paper
• Key enzyme in charge of ketone reabsorption of renal tubular SMCT1 may be a new target in diabetic kidney disease.

  2023cites this paper
• Dietary Management of Metabolic Liver Disease

  2023cites this paper
• Maleic acid is a biomarker for maleylacetoacetate isomerase deficiency; implications for newborn screening of tyrosinemia type 1

  2023cites this paper
• In vivo dissection of the mouse tyrosine catabolic pathway with CRISPR-Cas9 identifies modifier genes affecting hereditary tyrosinemia type 1

  2023cites this paper
• Hepatocellular carcinoma in an infant with tyrosinemia type 1

  2023cites this paper
• Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial

  2023cites this paper
• Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo

  2023cites this paper
• Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy.

  2023cites this paper
• The effects of phenylalanine and tyrosine levels on dopamine production in rat PC12 cells. Implications for treatment of phenylketonuria, tyrosinemia type 1 and comorbid neurodevelopmental disorders.

  2023cites this paper
• Alkaptonuria - Past, present and future.

  2023cites this paper
• Therapeutic applications of gene editing in chronic liver diseases: an update

  2022influential citation
• Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria

  2022cites this paper
• Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients

  2022influential citation
• Identification and antioxidant capacity of 4-hydroxyphenylpyruvate dioxygenase (HPPD), a new favored herbicide target, in Apis cerana cerana.

  2022cites this paper
• Improving the clinical accuracy and flexibility of the Alkaptonuria severity score index

  2022influential citation
• Long‐term low dose nitisinone therapy in adults with alkaptonuria shows no cognitive decline or increased severity of depression

  2022cites this paper
• Tyrosine Metabolism

  2022cites this paper
• Method development and validation for analysis of phenylalanine, 4‐hydroxyphenyllactic acid and 4‐hydroxyphenylpyruvic acid in serum and urine

  2022cites this paper
• Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria

  2022cites this paper
• Neurocognitive outcome and mental health in children with tyrosinemia type 1 and phenylketonuria: A comparison between two genetic disorders affecting the same metabolic pathway

  2022cites this paper
• Initial presentation, management and follow-up data of 33 treated patients with hereditary tyrosinemia type 1 in the absence of newborn screening

  2022cites this paper
• Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria

  2022cites this paper
• Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment

  2022cites this paper
• Novel Gene-Correction-Based Therapeutic Modalities for Monogenic Liver Disorders

  2022cites this paper
• Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector

  2022cites this paper
• mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model

  2022cites this paper
• Biochemical and behavioural profile of NTBC treated Tyrosinemie type 1 mice.

  2022cites this paper
• QM/MM study on the O2 activation reaction of 4-hydroxylphenyl pyruvate dioxygenase reveals a common mechanism for α-ketoglutarate dependent dioxygenase

  2022cites this paper
• The Discovery of the Mode of Action of Nitisinone

  2022cites this paper
• In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions

  2021cites this paper
• Abnormalities of Hepatic Protein Metabolism

  2021cites this paper
• Development of an Effective Therapy for Alkaptonuria – Lessons for Osteoarthritis

  2021cites this paper
• Liver Failure

  2021cites this paper
• Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

  2021cites this paper
• Physical Growth of Patients with Hereditary Tyrosinaemia Type I: A Single-Centre Retrospective Study

  2021cites this paper
• Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria—An approach using statistical modelling

  2021cites this paper
• Nitisinone treatment during two pregnancies and breastfeeding in a woman with tyrosinemia type 1 – a case report

  2021cites this paper
• Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities

  2021cites this paper
• Functional role of residues involved in substrate binding of human 4-hydroxyphenylpyruvate dioxygenase.

  2021cites this paper
• Treatment adherence in tyrosinemia type 1 patients

  2021cites this paper
• Targeting the Apoa1 locus for liver-directed gene therapy

  2021cites this paper
• Diagnostic and Therapeutic Challenges of Hereditary Tyrosinemia Type 1 in Lebanon: A 12-Year Retrospective Review

  2021cites this paper
• Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients

  2021influential citation
• Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I

  2021cites this paper
• Nitisinone: two decades treating hereditary tyrosinaemia type 1.

  2021cites this paper
• Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.

  2021cites this paper
• Repurposing the orphan drug nitisinone to control the transmission 2 of African trypanosomiasis 3 4

  2021cites this paper
• Development of Risk Prediction Equations for Incident Chronic Kidney Disease

  2020cites this paper
• Aspartame and Phe-Containing Degradation Products in Soft Drinks across Europe

  2020cites this paper
• Laboratory monitoring of patients with hereditary tyrosinemia type I.

  2020cites this paper
• The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening

  2020cites this paper
• Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis

  2020cites this paper
• Severe neurological crisis in adult patients with Tyrosinemia type 1

  2020cites this paper
• Somatic Liver Knockout (SLiK): A Quick and Efficient Way to Generate Liver‐Specific Knockout Mice Using Multiplex CRISPR/Cas9 Gene Editing

  2020cites this paper
• Liver Repopulation by Cell Transplantation and the Role of Stem Cells in Liver Biology

  2020cites this paper
• Genome editing technologies to treat rare liver diseases.

  2020cites this paper
• Combined 3D-quantitative structure-activity relationships and topomer technology-based molecular design of human 4-hydroxyphenylpyruvate dioxygenase inhibitors.

  2020cites this paper
• Type 1 tyrosinemia in Finland: a nationwide study

  2020cites this paper
• Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation

  2020cites this paper
• Case report: Maternal tyrosinemia type 1a under NTBC treatment with tyrosine‐ and phenylalanine restricted diet in Chile

  2020cites this paper
• High-throughput quantification of ochronotic pigment formation in Escherichia coli to evaluate the potency of human 4-hydroxyphenylpyruvate dioxygenase inhibitors in multi-well format

  2020cites this paper
• Disorders of phenylalanine and tyrosine metabolism

  2020cites this paper
• Tyrosinemia Type 1 – A case report

  2020cites this paper
• Clinical presentation and long-term outcomes of type 1 tyrosinemia in Finland: a nationwide study

  2020cites this paper
• Ex Vivo Cell Therapy by Ectopic Hepatocyte Transplantation Treats the Porcine Tyrosinemia Model of Acute Liver Failure

  2020cites this paper
• Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver.

  2020cites this paper
• CRISPR/Cas9-mediated gene correction in newborn rabbits with hereditary tyrosinemia type I.

  2020cites this paper
• Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.

  2020cites this paper
• Exploring the therapeutic potential of modern and ancestral phenylalanine/tyrosine ammonia-lyases as supplementary treatment of hereditary tyrosinemia

  2020cites this paper
• Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1

  2020cites this paper
• Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre

  2020cites this paper